| __timestamp | Exelixis, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2043000 | 5758000 |
| Thursday, January 1, 2015 | 3895000 | 8423000 |
| Friday, January 1, 2016 | 6552000 | 11986000 |
| Sunday, January 1, 2017 | 15066000 | 15215000 |
| Monday, January 1, 2018 | 26348000 | 15356000 |
| Tuesday, January 1, 2019 | 33097000 | 16660000 |
| Wednesday, January 1, 2020 | 36272000 | 52459000 |
| Friday, January 1, 2021 | 52873000 | 75061000 |
| Saturday, January 1, 2022 | 57909000 | 87221000 |
| Sunday, January 1, 2023 | 72547000 | 83779000 |
Unleashing the power of data
In the competitive landscape of biopharmaceuticals, understanding cost dynamics is crucial. Exelixis, Inc. and Supernus Pharmaceuticals, Inc. have shown intriguing trends in their cost of revenue from 2014 to 2023. Exelixis started with a modest cost of revenue in 2014, but by 2023, it surged by over 3,400%, reflecting its aggressive growth strategy. Meanwhile, Supernus Pharmaceuticals, with a more consistent trajectory, saw its costs increase by approximately 1,350% over the same period. This divergence highlights Exelixis's rapid expansion and investment in revenue-generating activities, while Supernus maintains a steady growth path. The year 2020 marked a pivotal point, with Supernus's costs surpassing Exelixis's, indicating a shift in market dynamics. These trends offer valuable insights into the strategic priorities and operational efficiencies of these two industry players.
Eli Lilly and Company vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.
Biogen Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Exelixis, Inc.
Cost of Revenue Comparison: Dr. Reddy's Laboratories Limited vs Exelixis, Inc.
Cost of Revenue Trends: Exelixis, Inc. vs Travere Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Exelixis, Inc. vs Galapagos NV
Analyzing Cost of Revenue: Jazz Pharmaceuticals plc and Supernus Pharmaceuticals, Inc.
Cost Insights: Breaking Down Lantheus Holdings, Inc. and Supernus Pharmaceuticals, Inc.'s Expenses
Amneal Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Supernus Pharmaceuticals, Inc. and Xencor, Inc.
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.'s Expenses